Ono Pharmaceutical Co Ltd (4528) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Ono Pharmaceutical Co Ltd (Ono Pharmaceutical) is a focuses on the research, development, manufacture and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes pharmaceuticals for the treatment of type II diabetes, overactive bladder, osteoporosis, Alzheimers disease, peripheral circulatory disorder, bronchial asthma and allergic rhinitis, among others. The company offers products in various formulations such as capsules, tablets, injections, patches, dry syrup and intravenous infusion. Ono Pharmaceutical also has products in pipeline development. It offers its products in Americas, Europe and Asia . Ono Pharmaceutical is headquartered in Chuo-ku, Osaka, Japan.

Ono Pharmaceutical Co Ltd (4528) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 7
List of Figures 7
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12
Ono Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 17
Partnerships 17
Ono Pharma Enters into Research Agreement with Schrodinger 17
Cyclenium Pharma Enters into Agreement with Ono Pharma 18
Neurimmune Therapeutics Enters into Co-Development Agreement with Ono Pharma 19
Ono Pharma Enters into Agreement with Eisai 20
Ono Pharma and Seikagaku Enter into Co-Development Agreement 21
Numab Therapeutics Enters into Research and Option Agreement with Ono Pharma 22
X-Chem Enters into Agreement with Ono Pharma 23
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 24
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 26
Ono Pharma Enters into Development Agreement with China Chemical & Pharma for Limaprost Alfadex 28
Dako Enters into Development Agreement with ONO PHARMA for Opdivo 29
Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 30
Bristol-Myers Squibb Enters into Co-Development Agreement with Ono Pharma 31
AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 33
Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 34
Ono Pharma Enters Into Drug Discovery Agreement With Domain Therapeutics 35
Ono Pharma Enters Into Discovery Agreement With BioFocus For CNS Drugs 36
Ono Pharma Enters Into Drug Discovery Agreement With BioFocus 37
Ono Pharma Enters Into Co-Development Agreement With Scil Proteins For Affilin Therapeutics 38
Licensing Agreements 39
Ono Pharma Enters into Licensing Agreement with Merus 39
Bristol-Myers Squibb Enters into Licensing Agreement with Ono Pharma for ONO-4578 40
ONO Pharma Enters into Licensing Agreement with Karyopharm Therapeutics 41
Ono Pharma Enters into Licensing Agreement with Array BioPharma 42
Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 43
Ono Pharma Enters into Licensing Agreement with Ligand Pharma 45
ONO Pharma Enters into Licensing Agreement with Celyad 46
ONO Pharma Enters into Licensing Agreement with IDAC Theranostics 47
Santen Pharma Enters into Licensing Agreement with Ono Pharma 48
Ono Pharma Enters into Licensing Agreement with Gilead Sciences for ONO-4059 49
Ono Pharma Exercises Option for Licensing Agreement with with Merus 50
Ono Pharma Enters Into Licensing Agreement With Bial For BIA 9-1067 51
Ono Pharma Enters Into Licensing Agreement With Genedata For Genedata Expressionist 52
Ono Pharmaceutical Co Ltd - Key Competitors 53
Ono Pharmaceutical Co Ltd - Key Employees 54
Ono Pharmaceutical Co Ltd - Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Recent Developments 57
Strategy And Business Planning 57
Mar 01, 2018: Ono Pharmaceutical Announce Completion of a New Tokyo Building 57
Corporate Communications 58
Jul 13, 2018: Ono Pharmaceutical: Support for the Torrential rain damage in Western Japan 58
Apr 05, 2018: Ono Pharmaceutical Announce on Candidates of Members of the Board of Directors and Corporate Officers 59
Government and Public Interest 60
May 30, 2018: Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development 60
Product News 61
11/30/2017: Cancer drug leads to drastic decrease in HIV infection in lung cancer patient 61
11/15/2017: LabCorp Announces New Expanded Use for PD-L1 Test with Bristol-Myers Squibbs OPDIVO 63
11/10/2017: Encouraging Response Observed with Opdivo (nivolumab) Plus Investigational IDO1 Inhibitor, BMS-986205, in Heavily Pre-Treated Patients with Advanced Cancers in Phase 1/2a Study CA017-003 64
11/07/2017: Opdivo (Nivolumab) Intravenous Infusion Approved in Taiwan for Expanded Use in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated with Platinum-based Therapy 66
10/30/2017: Opdivo (Nivolumab) Intravenous Infusion Approved in Taiwan for Additional Indications of Relapsed or Progressed Classical Hodgkin Lymphoma, Locally Advanced Unresectable or Metastatic Urothelial Carcinoma, and Unresectable or Metastatic Melanoma 67
09/22/2017: Bristol-Myers Squibbs Opdivo Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib 68
09/22/2017: Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Gastric Cancer Which Has Progressed After Chemotherapy 70
09/21/2017: Promising immunotherapy drug now available for some lung cancer patients in England 72
09/20/2017: Opdivo (Nivolumab) Intravenous Infusion Approved for Expanded Use in Advanced Non-squamous Non-small Cell Lung Cancer which Has Been Previously Treated with Platinum-based Therapy in Taiwan 73
09/20/2017: Nivolumab now available for lung cancer after company offers NICE new CDF deal 74
09/19/2017: Opdivo (Nivolumab) Intravenous Infusion Approved for Expanded Use in Unresectable or Metastatic Melanoma in South Korea 75
08/30/2017: Opdivo (Nivolumab) Intravenous Infusion Approved for Supplemental Indications of Advanced Renal Cell Carcinoma, Relapsed or Progressed Classical Hodgkin Lymphoma, Recurrent or Metastatic Head and Neck, Locally Advanced or Metastatic Urothelial Carcinoma, and Unresectable or Metastatic Melanoma in Combination with Ipilimumab in South Korea 76
08/16/2017: Opdivo Intravenous Infusion Approved for Supplemental Indication of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck with Disease Progression on or after Platinum-based Therapy in Taiwan 77
08/11/2017: FDA Approves Updated Indication for Opdivo (nivolumab) 78
08/01/2017: Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin, and Irinotecan 79
06/02/2017: NICE approves first use of Opdivo (nivolumab) in blood cancer 80
05/17/2017: Health Canada approves OPDIVO (nivolumab) for the treatment of squamous cell carcinoma of the head and neck 81
05/05/2017: White Blood Cell Count Predicts Response to Lung Cancer Immunotherapy 82
04/28/2017: European Commission Approves Bristol-Myers Squibbs Opdivo (nivolumab) for Squamous Cell Cancer of the Head and Neck in Adults Progressing On or After Platinum-based Therapy 83
04/24/2017: Opdivo (nivolumab) Designated for the Treatment of Biliary Tract Cancer Under the SAKIGAKE Designation System 85
04/21/2017: CHMP Adopts Extension To Existing Therapeutic Indication For Opdivo 86
04/21/2017: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer 87
04/03/2017: Patients with Lung Cancers Responsive to Immunotherapy Drug Beat Standard Odds of Survival 88
03/24/2017: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) for the Treatment of Squamous Cell Cancer of the Head and Neck in Adults Progressing on or After Platinum-based Therapy 90
03/24/2017: ONO Receives Approval for OPDIVO (Nivolumab) Intravenous Infusion for Treatment of Recurrent or Metastatic Head and Neck Cancer as a Partial Change in Approved Items of Manufacturing and Marketing Approval in Japan 91
03/22/2017: Ontario Latest Province to Cover Cost of Immuno-Oncology Treatment OPDIVO (nivolumab) 92
03/15/2017: Manitoba to Cover Immuno-Oncology Treatment OPDIVO (nivolumab) for Three Tumour Types 93
03/02/2017: British Columbia to Cover Immuno-Oncology Treatment OPDIVO (nivolumab) for Three Tumour Types 94
02/02/2017: Bristol-Myers Squibb Company Received Approval for Nivolumab by U.S. Food and Drug Administration for Treatment of Urothelial Carcinoma 95
Product Approvals 96
Oct 30, 2017: European Medicines Agency Validates Bristol-Myers Squibbs Type II Variation Application for Opdivo (nivolumab) for Treatment of Patients with Resected High-Risk Advanced Melanoma 96
Oct 16, 2017: U.S. Food and Drug Administration Accepts Bristol-Myers Squibbs Application for Opdivo (nivolumab) in Patients with Resected High-Risk Advanced Melanoma and Grants Priority Review 97
Sep 21, 2017: Withdrawal of the Application for a Change to the Marketing Authorisation for Nivolumab in EU 98
Sep 15, 2017: Withdrawal of the application for a change to the marketing authorisation for Opdivo (nivolumab) 99
Sep 11, 2017: Opdivo is accepted for restricted use within NHS Scotland 100
Jul 24, 2017: U.S. Food and Drug Administration Accepts Bristol-Myers Squibbs Applications for Opdivo (nivolumab) Four-Week Dosing Schedule Across All Approved Indications 101
Jul 10, 2017: SMC says yes to Opdivo (nivolumab) for blood cancer patients 102
Jun 12, 2017: SMC U-turn brings breakthrough immunotherapy Opdivo (nivolumab) to kidney cancer patients 103
Jun 02, 2017: European Commission Approves Bristol-Myers Squibbs Opdivo (nivolumab) for Previously Treated Locally Advanced Unresectable or Metastatic Urothelial Carcinoma in Adults After Failure of Prior Platinum-Containing Therapy 104
May 24, 2017: U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibbs Application for Opdivo (nivolumab) in Previously Treated Hepatocellular Carcinoma 106
Apr 04, 2017: U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibbs Application for Opdivo (nivolumab) in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer 107
Clinical Trials 108
Dec 05, 2017: U.S. Food and Drug Administration Lifts Partial Clinical Holds on Two Opdivo-based Combination Studies in Multiple Myeloma 108
Nov 30, 2017: CheckMate -078, a Pivotal, Multinational Phase 3 Opdivo (nivolumab) Lung Cancer Trial with Predominantly Chinese Patients, Stopped Early for Demonstrating Superior Overall Survival 109
Nov 29, 2017: Bristol-Myers Squibb to Present Clinical Trial Data of Antineoplastic Agent Nivolumab at the 59th Annual Meeting & Exposition of the American Society of Hematology 110
Nov 06, 2017: Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma 112
Oct 25, 2017: New Investigator Led Study Examining the Combination of SIR-Spheres Y-90 Resin Microspheres with Opdivo in HCC 113
Oct 13, 2017: NICE U-turn recommends head and neck cancer medicine which offers biggest increase in survival for 20 years 114
Oct 12, 2017: Stand Up To Cancer Awards Moffitt $2.67 Million to Study New Lung Cancer Immunotherapy 115
Sep 27, 2017: Bristol-Myers Squibb: Advancing Research Across Thoracic Cancers with New Data at IASLC 18th World Conference on Lung Cancer 116
Sep 10, 2017: Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) for Patients with Resected High-Risk Melanoma in Phase 3 CheckMate -238 Study 119
Sep 08, 2017: Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer 121
Sep 06, 2017: Bristol-Myers Squibb Provides an Update on Three Opdivo-based Combination Clinical Studies in Multiple Myeloma 123
Aug 30, 2017: Bristol-Myers Squibb Data at ESMO 2017 Demonstrate Companys Innovative Research Approach to Treating Cancer from All Angles 124
Jul 10, 2017: Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo in Combination with CABOMETYX or Opdivo and Yervoy in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma 130
Jul 05, 2017: Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint 131
Jun 21, 2017: First-line immunotherapy treatment can improve survival for subset of lung cancer patients 132
Jun 16, 2017: Extended Follow-Up Data Evaluating Opdivo (nivolumab) Shows Durable Response in Adult Patients with Relapsed or Progressed Classical Hodgkin Lymphoma 133
Jun 05, 2017: Encouraging Disease Control Rates Observed with Nivolumab Alone or in Combination with Ipilimumab in Refractory or Relapsing Malignant Pleural Mesothelioma Patients: Results from IFCT-1501 MAPS-2 Trial 134
Jun 02, 2017: Opdivo (nivolumab) Data in Patients with Advanced Cervical, Vaginal and Vulvar Cancers from Phase 1/2 CheckMate -358 Presented at ASCO 135
May 18, 2017: New trial to fight cancer caused by asbestos 137
Apr 11, 2017: Head and neck cancer patients set to miss out on first medicine to show biggest increase in survival for 20 years 139
Apr 04, 2017: Unprecedented 5-year follow-up shows long-term survival in lung cancer 140
Apr 03, 2017: Bristol-Myers Squibb Announces Results from CheckMate -143, a Phase 3 Study of Opdivo (nivolumab) in Patients with Glioblastoma Multiforme 142
Apr 03, 2017: Five-Year Survival Observed With Opdivo (nivolumab) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer, in Phase 1 Study CA209-003 143
Apr 03, 2017: Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) and Opdivo Monotherapy Significantly Improved Overall Survival Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma 145
Apr 02, 2017: Bristol-Myers Squibb and Incyte to Advance the Combination of Opdivo (nivolumab) and Epacadostat into First-line Registrational Trials 147
Jan 19, 2017: Opdivo (nivolumab) Demonstrated Efficacy and Improved Survival in Patients with Previously Treated Advanced Gastric Cancer in a Randomized Phase 3 Study 148
Appendix 150
Methodology 150
About GlobalData 150
Contact Us 150
Disclaimer 150

List Of Tables


Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
Ono Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 12
Ono Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Ono Pharma Enters into Research Agreement with Schrodinger 17
Cyclenium Pharma Enters into Agreement with Ono Pharma 18
Neurimmune Therapeutics Enters into Co-Development Agreement with Ono Pharma 19
Ono Pharma Enters into Agreement with Eisai 20
Ono Pharma and Seikagaku Enter into Co-Development Agreement 21
Numab Therapeutics Enters into Research and Option Agreement with Ono Pharma 22
X-Chem Enters into Agreement with Ono Pharma 23
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 24
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 26
Ono Pharma Enters into Development Agreement with China Chemical & Pharma for Limaprost Alfadex 28
Dako Enters into Development Agreement with ONO PHARMA for Opdivo 29
Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 30
Bristol-Myers Squibb Enters into Co-Development Agreement with Ono Pharma 31
AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 33
Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 34
Ono Pharma Enters Into Drug Discovery Agreement With Domain Therapeutics 35
Ono Pharma Enters Into Discovery Agreement With BioFocus For CNS Drugs 36
Ono Pharma Enters Into Drug Discovery Agreement With BioFocus 37
Ono Pharma Enters Into Co-Development Agreement With Scil Proteins For Affilin Therapeutics 38
Ono Pharma Enters into Licensing Agreement with Merus 39
Bristol-Myers Squibb Enters into Licensing Agreement with Ono Pharma for ONO-4578 40
ONO Pharma Enters into Licensing Agreement with Karyopharm Therapeutics 41
Ono Pharma Enters into Licensing Agreement with Array BioPharma 42
Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 43
Ono Pharma Enters into Licensing Agreement with Ligand Pharma 45
ONO Pharma Enters into Licensing Agreement with Celyad 46
ONO Pharma Enters into Licensing Agreement with IDAC Theranostics 47
Santen Pharma Enters into Licensing Agreement with Ono Pharma 48
Ono Pharma Enters into Licensing Agreement with Gilead Sciences for ONO-4059 49
Ono Pharma Exercises Option for Licensing Agreement with with Merus 50
Ono Pharma Enters Into Licensing Agreement With Bial For BIA 9-1067 51
Ono Pharma Enters Into Licensing Agreement With Genedata For Genedata Expressionist 52
Ono Pharmaceutical Co Ltd, Key Competitors 53
Ono Pharmaceutical Co Ltd, Key Employees 54
Ono Pharmaceutical Co Ltd, Other Locations 55
Ono Pharmaceutical Co Ltd, Subsidiaries 56

List Of Figures


Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 10
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12
Ono Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13

Synchronoss Technologies Inc (SNCR) - Financial and Strategic SWOT Analysis Review

Synchronoss Technologies Inc (SNCR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

Sonoco Products Co (SON) - Financial and Strategic SWOT Analysis Review

Sonoco Products Co (SON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

Pharmaceutical Competitive Intelligence, 2019: Abbvie Performance, Capabilities, Goals and Strategies

This report is part of the Competitive Analysis Series prepared by LeadingMarketResearch.com to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation

USD 850 View Report

Top 10 Pharmaceutical Companies Capabilities, Goals and Strategies

This report is part of the Competitive Analysis Series prepared by LeadingMarketResearch.com to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation

USD 4500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available